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Tyrosine hydroxylaseParadoxical sleep deprivation (PSD) increases pain sensitivity and reducesmorphine antinociception. Because
dopaminergic neurons in the periaqueductal gray matter (PAG) participate in pain modulation and opioid-
induced antinociception, we evaluated the effects of PSD on thermal pain sensitivity, morphine- and L-DOPA-
induced antinociception and dopaminergic functionality in the PAG by assessing tyrosine hydroxylase (TH)
immunoreactivity. Rats that were subjected to 96 h of PSD received vehicle, morphine (2.5, 5 or 10 mg/kg), L-
DOPA (50 or 100 mg/kg) or L-DOPA (50 mg/kg)+morphine (2.5 and 5 mg/kg) and were tested with a 46 °C
hot plate 1 h after. The paw withdrawal latency responses to the hot plate were decreased in PSD rats and
were modiﬁed by the highest dose of morphine, L-DOPA and L-DOPA+morphine. Analgesic effects were
observed in control groups for all of the morphine doses as well as 100 mg/kg of L-DOPA and L-DOPA (50 mg/
kg)+morphine (5 mg/kg). The number of cell bodies that were immunopositive for TH in the PAG was
reduced in PSD rats. In conclusion, increased thermal sensitivity was reversed by L-DOPA and could be caused
by a reduction TH levels in the PAG. Our data also suggest a relationship between central dopaminergic
networks and opiate-induced analgesia in rats.logia e Psicobiologia, Instituto
do Estado do Rio de Janeiro,
e Janeiro, Brazil. Tel.: +55 21
e Almeida).
vier OA license.© 2011 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Pain and sleep disturbances are closely correlated and previous
studies have demonstrated a bidirectional relationship between them.
Sleep disturbances are common in patients who experience acute and
chronic pain (Morin et al., 1998; Ohayon, 2005), and a number of
studies have focused on the effects of sleep loss in the context of pain
perception (Carli et al., 1987; Damasceno et al., 2009; Landis et al.,
1998; Lautenbacher et al., 2006; May et al., 2005; Nascimento et al.,
2007; Onen et al., 2001). Most sleep deprivation occurs during the
paradoxical-sleep/rapid-eye-movement (PS/REM) phase, which oc-
curs during the second half of the night. It is during this phase that
most restorative processes within the central nervous system (CNS)
and other parts of the body occur, and this is the reason for the
substantial number of studies that have focused on paradoxical sleep
deprivation (PSD).
Previous experiments have shown that pain sensitivity to noxious
stimuli is increased following PSD in healthy human subjects(Kundermann et al., 2004; Moldofsky et al., 1975; Moldofsky and
Scarisbrick, 1976; Roehrs et al., 2006) and experimental animals
(Hicks et al., 1979; May et al., 2005; Nascimento et al., 2007; Onen
et al., 2000, 2001). Onen et al. (2001) showed that 72 h of PSD lead to
a signiﬁcant increase in behavioral pain responses in rats when
challenged with mechanical, thermal and electrical stimuli. Experi-
mental animals that underwent 96 h of PSD showed a decrease in
paw-withdrawal responses to a noxious thermal stimulus (50 °C), and
this response persisted even after 24 h of sleep recovery (Nascimento
et al., 2007). These effects of PSD on nociception appear to be de-
pendent on the intensity of the noxious thermal stimuli and on the
age of the animal (May et al., 2005).
The mechanisms that govern the ability of PSD to change no-
ciceptive responses are still poorly understood. Many structures in the
brainstem that control sleep are also involved in the modulation of
pain processing (McCarley 2004; Pertovaara and Almeida, 2006).
Therefore, PSD may promote biochemical changes in the regions
involved in the modulation and control of pain. Several studies have
demonstrated that PSD can reduce the antinociceptive effect of
morphine (Ukponmwan et al., 1984), which suggests that normal PS
is important for the antinociceptive activity of endogenous and ex-
ogenous opiates.
The periaqueductal gray (PAG) plays an important role in no-
ciceptive modulation. Studies have correlated the antinociceptive
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brain areas (Manning et al., 1994; Pert and Yaksh 1975; Yaksh et al.,
1976). Alterations in neural transmission within the PAG modify the
antinociceptive effects of morphine (Lane et al., 2005), and electro-
physiological experiments suggest that opioids may activate the PAG
output neurons that project to the rostroventral medulla and the
spinal cord (Reichling and Basbaum, 1990).
There is a network of dopaminergic neurons within the vPAG. This
network is a part of the dorsocaudal A10 group of Hökfelt (Hökfelt
et al., 1976) and is composed of both small and large neurons (Hasue
and Shammah-Lagnado, 2002). Dopamine (DA) neurons of the PAG
region that project locally or to different brain structures may com-
municate with neural areas that are involved in the affective aspects
of pain (Hasue and Shammah-Lagnado, 2002; Ottersen, 1981).
Dopaminergic neuron depletion in the vPAG with 6-hydroxydo-
pamine (6-OHDA) decreases opioid-induced antinociception in rats
(Flores et al., 2004), and a recent study suggests that DA may have
a direct antinociceptive effect in addition to the modulation of the
antinociceptive effects of morphine (Meyer et al., 2009). Both D1 and
D2 dopamine receptors are expressed by PAG neurons. D1 receptors
are associated with morphine analgesia (Flores et al., 2004), and D2
receptors are associated with dopamine analgesia (Meyer et al.,
2009).
Previous studies have demonstrated that tyrosine hydroxylase
(TH), the enzyme that catalyzes the rate-limiting step of catechol-
amine biosynthesis, is sensitive to periods of PSD (Damasceno et al.,
2008), which makes TH an interesting marker that may be used to
understand the correlation between the dopaminergic system and
PSD.
Therefore, we hypothesized that the increase in pain sensitivity
that is observed after periods of PSDmight be related to a reduction in
dopaminergic functionality in the PAG. In this study, we assessed the
effect of PSD on thermal pain sensitivity, morphine- and L-DOPA (a DA
precursor)-induced antinociception and dopaminergic functionality
in the PAG by the measurement of TH immunoreactivity.
2. Materials and methods
2.1. Animals
Adult male Wistar rats (250–300 g) were used. The rats were
housed in cages with free access to food and water in a room under
controlled light/dark cycle conditions (12 h light/12 h dark; lights on
at 6:00 a.m.) and ambient temperature (23±1 °C). All experimental
protocols complied with the ethical guidelines for investigations of
experimental pain in conscious animals andwere previously approved
by The Animal Studies Ethical Committee of the State University of Rio
de Janeiro (CEUA/032/2010).
2.2. Paradoxical sleep-deprivation procedure
The method used to induce PSD was the “inverted ﬂower pot”
technique (Jouvet et al., 1964) for 96 h. In this technique, rats were
placed individually in tanks on circular platforms (6 cm in diameter)
that were surrounded by water. When the animals entered the par-
adoxical phase of sleep, they lost skeletal muscle tone, fell into the
water andwere awakened. Food andwater were easily accessible. The
control groups were maintained in cages in the same room for the
duration of the study.
2.3. Hot-plate test
Thermal hyperalgesia responses were assessed using the hot-plate
test (Lejca Scientiﬁc Instruments, Barcelona, Spain) at a temperature of
46 °C. The experiments were videotaped and evaluated by 2 indepen-
dent observers who were blinded to the experimental conditions. Theresults represent themean latency of the removal of 1 of the hind paws
from the hot plate apparatus (i.e., paw withdrawal latency). To avoid
paw damage, a cutoff of 90 s was established.
2.4. Experimental design
Immediately after 96 h of PSD, rats in both the control and PSD
groups were tested on the hot plate to evaluate thermal sensi-
tivity. Vehicle (physiological saline), morphine (2.5, 5 and 10 mg/kg,
Cristália — Brazil) or L-DOPA (50 and 100 mg/kg, Sigma-Aldrich —
USA) was intraperitoneally administered to both control and PSD rats
(n=8 per group) 1 h before the hot-plate test. In another experiment,
L-DOPA (50 mg/kg) was administrated 30 min before treatment
with morphine (2.5 and 5 mg/kg). In all experiments, L-DOPA was
combined with benserazide, a peripheral decarboxylase inhibitor, at a
dose ratio of 4:1 dissolved in 0.2 M HCl (in physiological saline), and
the solution was adjusted to a pH of 6.8 (for details, see Paalzow,
1992).
2.5. Tissue preparation and TH immunohistochemistry
Immediately after 96 h of PSD, rats (n=7 per group) from the
control and PSD groupswere anesthetizedwith thiopental (70 mg/kg)
and transcardially perfused with 0.9% NaCl, which was followed
sequentially by 4% paraformaldehyde in phosphate buffer and 4%
paraformaldehyde with 10% sucrose. After perfusion, the brains were
removed and immersed overnight in 20% sucrose in phosphate buffer
at 4 °C for cryoprotection prior to sectioning. After each brain was
frozen, 30-μm coronal sections were obtained and collected on
gelatinized slides.
Eight 30-μm sections, each separated by 90 μm, were collected and
processed for immunohistochemistry. The ﬁrst section was collected
at approximately−7.64 mmfrom the bregma, and the last sectionwas
collected −8.72 mm from the bregma (vPAG) (Paxinos and Watson,
1998).
Immunohistochemistry was conducted according to the avidin–
biotin-peroxidase protocol (ABC Elite kit; Vector). The sections were
incubated in phosphate-buffered saline/0.2% Triton X-100 (PBS-T)with
10% normal goat serum (Vector) for 2 h to block nonspeciﬁc binding.
Sections were incubated for 72 h at 4 °C with a rat anti-tyrosine-
hydroxylase polyclonal antibody (AB 151, Chemicon, 1:5,000) in PBS-T,
and afterwashing in PBS, theywere incubated for 18 hwith biotinylated
goat anti-rabbit-IgG (Santa Cruz) diluted 1:200. Additional washes in
PBS were performed, and the sections were incubated for 2 h with the
ABC kit (1:50).
Finally, the sections were reacted with the SG chromogen and a
hydrogen peroxide solution (Vector SG kit) and analyzed for the
number of cells that expressed TH (i.e., those with a blue SG label in
the soma and dendrites). Positive cells distributed throughout the
vPAG were counted in each coronal section. The microscopic counting
analysis was performed by an investigator who was blinded to the
experimental conditions. Data represent the average cell count from
8 sections.
Control sections were incubated with normal goat serum with the
omission of the primary antibody and immunoreactivity detection. All
sections were examined under light microscopy using an Olympus BX
40 microscope. Images were captured with a cooled charged–coupled
device camera (Sony DXC 151A).
2.6. Statistics
The results are presented as a mean±S.E.M., and all data analyses
were performed using GraphPad Prism 5.0 (GraphPad Software, Inc.,
USA). One-way analysis of variance (ANOVA) was used for compar-
isons of data between the doses followed by the Newman–Keuls test
for post-hoc comparisons. Differences between the control and PSD
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were determined using Student's unpaired two-tailed t-test. Results
were considered to be statistically signiﬁcant when p≤0.05.
3. Results
3.1. Nociceptive behavior
As shown in Fig. 1, PSD for 96 h signiﬁcantly decreased the paw
withdrawal latency in rats that received vehicle (−75.89%, p≤0.05).
As expected, acute treatment with 2.5, 5 and 10 mg/kg morphine
increased paw withdrawal latency in non-sleep-deprived rats
(54.45%, 75.37% and 63.89%, respectively) (Fig. 1A). In sleep-deprived
rats, acute treatment with 2.5 or 5 mg/kg morphine did not increase
paw withdrawal latency; however, a signiﬁcant effect was observed
with the highest dose (10 mg/kg) (p≤0.05).Fig. 1. Effects of acute treatment withmorphine, L-DOPA and L-DOPA plus morphine on
hind pawwithdrawal latencies in control and paradoxical sleep deprived rats submitted
to a hot-plate test (46 °C) after 96 h of paradoxical sleep deprivation. (A) Morphine was
administered intraperitoneally in 3 different doses (2.5, 5 or 10 mg/kg), 60 min prior to
the test. (B) The dopamine precursor, L-DOPA, and the DOPA decarboxylase inhibitor,
benserazide (at a 4:1 ratio) were administered intraperitoneally in 2 different doses
(50 or 100 mg/kg) 60 min prior to the test. (C) L-DOPA (50 mg/kg) andmorphine (2.5 or
5 mg/kg) were administrated 90 and 60 min prior to the test, respectively. Each column
represents the mean±SEM of eight rats. * p-value≤0.05 differs from the respective
control group (unpaired t-test), # p-value≤0.05 differs from the respective saline group
(one-way ANOVA followed by Newman–Keuls test).The treatments with L-DOPA at 50 and 100 mg/kg increased paw
withdrawal latency in sleep-deprived rats (+346.61% and +256.65%,
respectively; p≤0.05) (Fig. 1B). In control rats, this effect was
observed at the highest dose of L-DOPA (+76%, p≤0.05) and after
L-DOPA 50 mg/kg plus morphine 5 mg/kg treatment (+49,28%,
p≤0.05) (Fig. 1B and C). However, the combination of L-DOPA plus
morphine in all of the doses evaluated did not increase the L-DOPA
analgesic effect in sleep-deprived rats (Fig. 1C).
3.2. Tyrosine hydroxylase immunohistochemistry
In control rats, the distribution of cells expressing TH was similar
to previous reports (Flores et al., 2004). Immunostaining was present
throughout the cell body andwas predominant in the eminence of the
main neurite. Moreover, TH-positive neurons were observed through-
out the vPAG and consisted of large cells located in the lateral area and
smaller neurons surrounding the aqueduct of Sylvius (Fig. 2). In this
experiment, only the large neurons were counted. Sleep-deprived
rats exhibited a signiﬁcant reduction (−31.5%) in the number of TH-
immunoreactive cells in the PAG compared to controls (Figs. 2 and 3).
4. Discussion
Our results clearly demonstrate that 96 h of PSD signiﬁcantly
increased the pain sensitivity of animals subjected to a noxious thermal
stimulus (46 °C). We also evaluated the effects of acute morphine
treatment on PSD-induced hyperalgesia. Morphine reversed this hyper-
algesia but only at thehighest of the 3doses administered. In addition,we
tested the role of dopamine in this reversal by the administration of
L-DOPA (with and without morphine) and through the quantiﬁcation of
the number of TH-immunoreactive cellular bodies in the vPAG of sleep-
deprived and control rats. L-DOPA alone prevented PSD-induced
hyperalgesia. The immunohistochemical analysis revealed a reduction
in the number of TH-immunoreactive cell bodies in sleep-deprived rats.
Our results are consistent with the results obtained by Nascimento
et al. (2007), who reported that 96 h of PSD reduced the latency of
paw withdrawal in animals subjected to a thermal stimulus at 50 °C.
Onen et al. (2001) also showed that PSD for 72 h reduced the pain
threshold for thermal stimuli as determined by the tail ﬂick test. Based
on the subsequent type of nociceptive ﬁber activation, PSD appears to
increase the pain sensitivity of rats in a manner that is independent of
the noxious temperature (Damasceno et al., 2009). However, in our
study, the noxious temperature was set at 46 °C, which predomi-
nantly activates C nociceptive ﬁbers (May et al., 2005) that express
μ-opioid receptors. We used this experimental paradigm to observe
morphine antinociception.
Previous studies have investigated opioid systems in PSD-induced
hyperalgesia in rats. Ukponmwan et al. (1984, 1986) have shown that
the analgesic effects of phosphoramidon and morphine are abolished
after 96 h of PSD. Nascimento et al. (2007) also demonstrated that PSD
may reduce the antinociceptive effect of morphine because the acute
administration of 2.5 and 5 mg/kg morphine did not alter the paw
withdrawal response of rats challenged with a noxious temperature of
50 °C. These data suggest that PS is important for the antinociceptive
activity of opiates. Similarly, in our study, we concluded that PSD
reduced the antinociceptive effects of morphine at the same doses in
rats tested at 46 °C on a hot plate. We only observed an increase in
the hind paw withdrawal latency at the highest dose of morphine,
10 mg/kg. Morphine treatment with 10 mg/kg, but not 3 mg/kg
decreases locomotor activity (Smith et al., 2009). Therefore, it is im-
portant to note that the reduction in hind paw response at 10 mg/kg
may be due to a secondary reduction in locomotor activity rather than
an analgesic effect.
Themechanism bywhich these PSD-induced changes occur during
the nociceptive responses is unclear, but several lines of evidence
suggest that these alterations may result from changes in different
Fig. 2. Photomicrographs of periaqueductal gray matter immunostained with an antibody to tyrosine hydroxylase. (a, c, e) Coronal sections from control rats showing dense tyrosine
hydroxylase labeling in the periaqueductal gray matter. (b, d, f) Coronal sections from paradoxical sleep-deprived rats showing a reduction in tyrosine hydroxylase immunostaining
in the periaqueductal gray matter. The black arrows indicate large cells, and the black arrowheads indicate small cells. Aq, aqueduct of Sylvius. Scale bars represent 50 μm (a, b),



















Fig. 3. Number of large tyrosine hydroxylase immunoreactive cells counted in the
ventrolateral periaqueductal gray matter of the control (n=7) and paradoxical sleep-
deprived (n=7) groups. Data are presented as mean±SEM. *p value≤0.05 differs
from the control group (unpaired t-test).
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suggested that animals subjected to PSD exhibit a low level of activity
at the receptors for endogenous opioid peptides (Ukponmwan et al.,
1986). In fact, these receptors are reduced in animals deprived of PS
(Fadda et al., 1991). PSD also promotes the inhibition of opioid protein
synthesis (Shapiro and Girdwood, 1981) and modiﬁes μ-opioid
receptor binding in limbic areas of the brain (Fadda et al., 1991).
However, Nascimento et al. (2007) reported no differences in μ-opioid
receptor binding in brain regions that are involved in pain control,
which suggests that other neurotransmitter systems may be involved
in PSD-induced changes in the response to morphine.
DA is a neurotransmitter that is associated with several of the
behavioral changes observed after PSD. An increase in receptor sen-
sitivity (see for a review: Tuﬁk et al., 2009) and DA release after 24 h
of total sleep deprivation has been described (Volkow et al., 2008);
however, no signiﬁcant alterations of dopamine transporters have
been observed (Martins et al., 2010).
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nociception within supraspinal regions andmodulates the antinocicep-
tive effect of morphine on the PAG (Paalzow, 1992; Wood, 2008).
L-DOPAhas beenused to treat pain associatedwithdiabetic neuropathy,
bone metastasis and herpes zoster (Nixon, 1975; Ertas et al., 1998;
KernbaumandHauchecome, 1981), and the analgesic effect occurs after
conversion to dopamine, which acts on D2 receptors (Shimizu et al.,
2004).
In this study, L-DOPAwas administeredwith benserazide to prevent
its peripheral decarboxylation, and reversed the hyperalgesia induced
by PSD; an analgesic effect of L-DOPA in control ratswas observed at the
highest dose administered. The combination of L-DOPA 50 mg/kg and
morphine did not increase the analgesic effects of L-DOPA because the
paw withdrawal latencies of control and sleep-deprived rats treated
withmorphinewere in the same range regardless of whethermorphine
administration was accompanied by L-DOPA (Fig. 1A and C). However,
the paw withdrawal latencies in the control group were similar for the
highest doses of morphine (Fig. 1A) and L-DOPA (Fig. 1B). These data
indicate that central dopamine had a direct effect on PSD-induced
hyperalgesia and suggest a relationship between the central dopami-
nergic network and opiate-induced analgesia in rats. In fact, the vPAG
features dopaminergic neurons that are associated with this opiate
response. Depletion of these neurons using 6-hydroxydopamine
(6-OHDA) or through intracerebral injections of D1 DA receptor
antagonists into the vPAG reduces the analgesic action of morphine
(Flores et al., 2004). Recently, another group has provided evidence for
the role of DA in the modulation of nociception in the PAG. Meyer et al.
(2009) have shown that DA inhibits the GABAergic system in the vPAG
in a manner similar to opioids.
In this study, we observed and quantiﬁed the labeling of do-
paminergic neurons in the vPAG of sleep-deprived and control rats
using TH immunoreactivity. TH activity is regulated by feedback
inhibition and phosphorylation, and TH also undergoes transcriptional
and translational regulation that is induced by changes in the phys-
iological state (for a review, see Kumer and Vrana, 1996). Immuno-
histochemical analysis revealed a reduction in the number of cell
bodies labeledwith TH in PSD animals. Flores et al. (2004) showed that
the dopaminergic circuitry in the PAG is composed of 2 different types
of neurons (large and small) and reported that large neurons
participate in supraspinal nociceptive responses. Large neurons,
which also exhibit a multipolar morphology and abundant arboriza-
tion, are often located adjacent to the PAG. Small cells exhibit a
roundedmorphology and aremore frequently located in the vicinity of
the surface of the aqueduct of Sylvius. In our study, we observed the 2
dopaminergic cell types described previously in the literature. Sleep-
deprived rats showed small dopaminergic neurons in regions closer
to the aqueduct of Sylvius and a reduction in the number of large
dopaminergic neurons.
Meyer et al. (2009) has suggested that there may be synaptic
connections between dopaminergic and GABAergic neurons in the
vPAG, which implicates the participation of dopaminergic neurons in
analgesia. Considering the involvement of vPAG dopaminergic
neurons in the response to opioid drugs and our observations of the
antinociceptive effect of L-DOPA and the TH labeling in sleep-deprived
rats, we suggest that there is a relationship between the behavioral
data and the observed alterations in TH immunohistochemistry. The
reducing in TH staining in sleep-deprived rats indicated a reduction in
dopaminergic activity in the vPAG. This eventmight be associatedwith
a decrease in endogenous analgesic mechanisms, which resulted in an
increased sensitivity to painful stimuli and with the changes observed
in the antinociceptive responses that were induced by morphine.
5. Conclusions
Our data suggest that PSD could interfere with dopaminergic
transmission in the PAG as indicated by the observed reduction in THstaining and the L-DOPA-induced decrease in PSD-hyperalgesia.
Moreover, the changes induced in the dopaminergic system may be
associated with an increase in the sensitivity to noxious stimuli and
changes in the antinociceptive response induced by morphine.Acknowledgments
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